Minerva Neurosciences

$2.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.00 (+0.21%) As of 2:22 PM UTC today

Why Robinhood?

You can buy or sell NERV and other stocks, options, and ETFs commission-free!

About NERV

Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.

CEO
Rémy Henri Luthringer
Employees
11
Headquarters
Waltham, Massachusetts
Founded
2007
Market Cap
102.44M
Price-Earnings Ratio
56.33
Dividend Yield
—
Average Volume
294.75K
High Today
$2.45
Low Today
$2.40
Open Price
$2.44
Volume
36.01K
52 Week High
$15.22
52 Week Low
$1.81

NERV Earnings

-$0.77
-$0.27
$0.23
$0.73
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 3, Pre-Market

You May Also Like

RWJ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure